Ronald W. McClurg
Known title: Chief Financial OfficerCIK: 0001837830
Ronald W. McClurg's purchase track record
How the stock did after each of Ronald W. McClurg's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since May 20, 2022
Stock higher 6 months later
75%
3 months: 100%
Median 6-month return
+53.9%
3 months: +62.9%
Beat the S&P 500
50%
median +29.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/4/2025 | NMTC | $100K | +53.9% | +95.8% | +32.4% |
| 9/13/2023 | NMTC | $50K | +53.0% | +12.0% | +15.6% |
| 6/10/2022 | NMTC | $25K | +72.0% | +163.5% | +0.9% |
| 5/20/2022 | NMTC | $25K | +85.7% | -8.8% | +1.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NMTC | ▲ Buy | Open Market | 200,000 | $100K | 4/4/2025 | View on chart |
| NMTC | ▲ Buy | Grant | 113,717 | $0 | 2/18/2024 | View on chart |
| NMTC | ▲ Buy | Open Market | 50,900 | $50K | 9/13/2023 | View on chart |
| NMTC | ▲ Buy | Grant | 12,500 | $0 | 4/21/2023 | View on chart |
| NMTC | ▲ Buy | Open Market | 10,000 | $10K | 6/15/2022 | View on chart |
| NMTC | ▲ Buy | Open Market | 14,000 | $15K | 6/10/2022 | View on chart |
| NMTC | ▲ Buy | Open Market | 10,500 | $10K | 5/24/2022 | View on chart |
| NMTC | ▲ Buy | Open Market | 17,500 | $15K | 5/20/2022 | View on chart |
| NMTC | ▲ Buy | Grant | 15,000 | $0 | 2/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NeuroOne Reports Strong Q4 Sales, New $4.5M Order
NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.
NeuroOne Reports Strong Q4 Sales, New $4.5M Order. NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.